Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
Mangiacavalli S, Albani G, Caravita T, Cocito F, Pascutto C, Zappasodi P, Bringhen S, Palumbo A, Cazzola M, Corso A. Mangiacavalli S, et al. Among authors: corso a. Leuk Lymphoma. 2012 Mar;53(3):514-5. doi: 10.3109/10428194.2011.600487. Epub 2011 Dec 5. Leuk Lymphoma. 2012. PMID: 22141736 Clinical Trial. No abstract available.
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, Pascutto C, Varettoni M, Bernasconi P, Grillo G, Carella AM, Montalbetti L, Lazzarino M, Morra E. Corso A, et al. Leuk Lymphoma. 2010 Feb;51(2):236-42. doi: 10.3109/10428190903452826. Leuk Lymphoma. 2010. PMID: 20001242 Clinical Trial.
Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
Mangiacavalli S, Pochintesta L, Ravelli E, Baldini L, Ferretti VV, La Targia ML, Farina L, Cocito F, Cairoli R, Montefusco V, Corso A. Mangiacavalli S, et al. Among authors: corso a. Leuk Lymphoma. 2015 Jun;56(6):1901-2. doi: 10.3109/10428194.2014.979414. Epub 2015 Jan 14. Leuk Lymphoma. 2015. PMID: 25347423 Clinical Trial. No abstract available.
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Pozzi S, Gentile M, Sacchi S, Marcheselli R, Corso A, Cocito F, Musto P, Guarini A, Minoia C, Vincelli I, Ria R, Rivolti E, Mele G, Bari A, Mazzone C, Badiali S, Marcheselli L, Palumbo A, Morabito F. Pozzi S, et al. Among authors: corso a. Leuk Lymphoma. 2017 Mar;58(3):552-559. doi: 10.1080/10428194.2016.1205741. Epub 2016 Jul 21. Leuk Lymphoma. 2017. PMID: 27442600 Clinical Trial.
Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report.
Cocito F, Mangiacavalli S, Bernasconi P, Colombo AA, Caldera D, Cartia CS, Ganzetti M, Troletti D, Cazzola M, Corso A. Cocito F, et al. Among authors: corso a. Leuk Lymphoma. 2017 Nov;58(11):2770-2771. doi: 10.1080/10428194.2017.1300890. Epub 2017 Mar 13. Leuk Lymphoma. 2017. PMID: 28287281 No abstract available.
473 results